LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses growth accelerates

Q1 FY2026 other income / expenses of $2.65M rose 14.5% year over year, ahead of the -15.9% change in trailing-twelve-month other income / expenses. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at +694.1% a year.

Context

  • Other income / expenses amounted to 49.8% of revenue in FY2025.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of -15.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.65M+3.0% QoQ
Last fiscal yearDec 2025
$9.51M+7.6% YoY
LTMMar 2026
$9.85M-15.9% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.5%——
1 year+7.6%——
3-year CAGR+694.1%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
9.51M USD
Year-over-year change
+7.6%

Other Income / Expenses vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.9% is the 4th highest of 11, against a peer median of -46.7%.
  • Other income / expenses amounts to 46.9% of revenue for LENZ, versus a peer median of 30.4%.
LENZ Competitors
Other Income / Expenses for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TYRATyra Biosciences, Inc.LTM Mar 2026$11.81M USD-31.7%+52.7%—
GHRSGH Research PLCLTM Mar 2026$10.27M USD+9.2%+15.3%—
LENZLENZ Therapeutics, Inc.LTM Mar 2026$9.85M USD-15.9%+694.1%46.9%
PRMEPrime Medicine, Inc.LTM Mar 2026$8.24M USD+88.4%—204.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$6.05M USD-59.8%—3.2%
RZLTRezolute, Inc.LTM Mar 2026$5.77M USD+39.1%+91.3%—
SVRASavara Inc.LTM Mar 2026$4.63M USD-33.6%+89.8%—
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$4.36M USD-62.8%+113.1%4.4%
NBTXNanobiotix S.A.FY2025-€13.14M EUR-3739.9%—44.3%
GERNGeron CorporationLTM Mar 2026-$32.22M USD-583.4%—16.4%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$232.58M USD-785.1%—111.4%
Peer median (excluding LENZ) —-46.7%+89.8%30.4%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.